Comparative Pharmacology
Head-to-head clinical analysis: HICON versus SANCTURA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HICON versus SANCTURA.
HICON vs SANCTURA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
Trospium chloride is an antimuscarinic agent that competitively inhibits acetylcholine at muscarinic receptors, thereby reducing detrusor muscle contractions and increasing bladder capacity.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
20 mg orally twice daily, with or without food. Maximum dose 20 mg twice daily.
None Documented
None Documented
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is approximately 12–20 hours in healthy adults, allowing twice-daily dosing.
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Primarily renal (approximately 60% as unchanged drug and metabolites); biliary/fecal elimination accounts for ~30%.
Category C
Category C
Anticholinergic
Anticholinergic